Literature DB >> 21314837

What blood temperature for an ex vivo extracorporeal circuit?

Thomas Rimmelé1, Jeffrey Bishop, Peter Simon, Melinda Carter, Lan Kong, Minjae Lee, Kai Singbartl, John A Kellum.   

Abstract

Ex vivo circuits are commonly used to evaluate biomaterials or devices used for extracorporeal blood purification. However, various aspects of the ex vivo circuit, apart from the circuit materials, may affect inflammation and coagulation. One such aspect is temperature. The aim of this study was to evaluate the influence of different blood temperature conditions on inflammation parameters in an ex vivo circuit. Blood was collected from 20 healthy volunteers and run through three different experimental conditions for 4 h: a miniaturized ex vivo extracorporeal circuit equipped with a blood warmer set to 37°C, the same circuit without the warmer (23°C), and a tube placed in an incubator at 37°C (no circuit). We measured the granulocyte macrophage colony-stimulating factor, the tumor necrosis factor, and the interleukin (IL)-1β, IL-6, IL-8, and IL-10 concentrations at baseline, 15, 60, 120, and 240 min. Human leukocyte antigen (HLA)-DR, CD11b, CD11a, CD62L, tumor necrosis factor alpha converting enzyme, annexin V expression, and NFkB DNA binding were measured in monocytes and polymorphonuclear neutrophils (PMNs) using flow cytometry at baseline, 120 min, and 240 min. While cytokine production over time was very slight at room temperature, levels increased by more than 100-fold in the two heated conditions. Differences in the expression of some surface markers were also observed between the room temperature circuit and the two heated conditions (CD11b PMN, P < 0.0001; HLA-DR Mono, P=0.0019; and CD11a PMN, P<0.0001). Evolution of annexin V expression was also different over time between the three groups (P=0.0178 for monocytes and P=0.0011 for PMNs). A trend for a greater NFkB DNA binding was observed in the heated conditions. Thus, for ex vivo studies using extracorporeal circuits, heating blood to maintain body temperature results in significant activation of inflammatory cells while hypothermia (room temperature) seems to suppress the leukocyte response. Both strategies may lead to erroneous conclusions, possibly masking some specific effects of the device being studied. Investigators in this field must be aware of the fact that blood temperature is a crucial confounding parameter and the type of "background noise" they will face depending on the strategy adopted.
© 2011, Copyright the Authors. Artificial Organs © 2011, International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21314837      PMCID: PMC3224854          DOI: 10.1111/j.1525-1594.2010.01147.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  27 in total

Review 1.  Biomaterials in cardiopulmonary bypass.

Authors:  J M Courtney; X Zhao; H Qian
Journal:  Perfusion       Date:  1999-07       Impact factor: 1.972

Review 2.  Influence of hypothermia on post-ischemic inflammation: role of nuclear factor kappa B (NFkappaB).

Authors:  Midori A Yenari; Hyung Soo Han
Journal:  Neurochem Int       Date:  2006-06-05       Impact factor: 3.921

3.  Neutrophil activation in paediatric extracorporeal circuits: effect of circulation and temperature variation.

Authors:  M H el Habbal; H Carter; L J Smith; M J Elliott; S Strobel
Journal:  Cardiovasc Res       Date:  1995-01       Impact factor: 10.787

4.  Removal of cytokines and activated complement components in an experimental model of continuous plasma filtration coupled with sorbent adsorption.

Authors:  C Tetta; J M Cavaillon; M Schulze; C Ronco; P M Ghezzi; G Camussi; A M Serra; F Curti; G Lonnemann
Journal:  Nephrol Dial Transplant       Date:  1998-06       Impact factor: 5.992

5.  Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits.

Authors:  G S Aldea; P O'Gara; O M Shapira; P Treanor; A Osman; E Patalis; C Arkin; R Diamond; V Babikian; H L Lazar; R J Shemin
Journal:  Ann Thorac Surg       Date:  1998-02       Impact factor: 4.330

6.  Effect of moderate hypothermia on systemic and internal jugular plasma IL-6 levels after traumatic brain injury in humans.

Authors:  M Aibiki; S Maekawa; S Ogura; Y Kinoshita; N Kawai; S Yokono
Journal:  J Neurotrauma       Date:  1999-03       Impact factor: 5.269

7.  Increased matrix metalloproteinase-9 in blood in association with activation of interleukin-6 after traumatic brain injury: influence of hypothermic therapy.

Authors:  Eiichi Suehiro; Hirosuke Fujisawa; Tatsuo Akimura; Hideyuki Ishihara; Koji Kajiwara; Shoichi Kato; Masami Fujii; Susumu Yamashita; Tsuyoshi Maekawa; Michiyasu Suzuki
Journal:  J Neurotrauma       Date:  2004-12       Impact factor: 5.269

8.  Acute renal failure in critically ill patients: a multinational, multicenter study.

Authors:  Shigehiko Uchino; John A Kellum; Rinaldo Bellomo; Gordon S Doig; Hiroshi Morimatsu; Stanislao Morgera; Miet Schetz; Ian Tan; Catherine Bouman; Ettiene Macedo; Noel Gibney; Ashita Tolwani; Claudio Ronco
Journal:  JAMA       Date:  2005-08-17       Impact factor: 56.272

9.  The role of inflammatory processes in the pathophysiology and treatment of brain and spinal cord trauma.

Authors:  W D Dietrich; K Chatzipanteli; E Vitarbo; K Wada; K Kinoshita
Journal:  Acta Neurochir Suppl       Date:  2004

10.  Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.

Authors:  Dennis T Mangano; Yinghui Miao; Alain Vuylsteke; Iulia C Tudor; Rajiv Juneja; Daniela Filipescu; Andreas Hoeft; Manuel L Fontes; Zak Hillel; Elisabeth Ott; Tatiana Titov; Cynthia Dietzel; Jack Levin
Journal:  JAMA       Date:  2007-02-07       Impact factor: 56.272

View more
  1 in total

1.  Expression of CD11b (MAC-1) and CD162 (PSGL-1) on monocytes is decreased under conditions of deep hypothermic circulatory arrest.

Authors:  Stefanie Swoboda; Joachim Gruettner; Siegfried Lang; Hans-Peter Wendel; Martin E Beyer; Eva Griesel; Hans-Martin Hoffmeister; Thomas Walter
Journal:  Exp Ther Med       Date:  2014-05-28       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.